![Screenshot of title and primary endpoint of plain language media summary on SUNNY trials results ](/sites/novartis_com/files/styles/webp/public/2023-02/primary-endpoint-media-summary-sunny-trials-results-preview.jpg.webp?itok=VByyuABq "Screenshot of title and primary endpoint of plain language media summary on SUNNY trials results ") 

Description

Discover the data published in *The Lancet* on the long-term effect of Cosentyx® (secukinumab) in adults with hidradenitis suppurativa from the SUNRISE and SUNSHINE trials.



 

 

Usage Rights & Restrictions

This media asset is free for editorial broadcast, print, online and radio use. It is restricted for other purposes.



 

 [ Download (PDF 1.11 MB)  ](https://www.novartis.com/sites/novartis_com/files/secukinumab-sunny-trials-in-hidradenitis-suppurativa-16-52-week-data-infographic.pdf)